newsfilter
← Latest News
GlobeNewswire·

ObsEva Announces IND Approval for Yuyuan Bioscience's Phase 1 Clinical Trial of Nolasiban in China

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 13, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN)), a biopharmaceutical company developing novel therapies for women's